The North America Syphilis Testing Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).
Syphilis is the only sexually transmitted infection (STI) for which a low-cost, quick complete blood count is available. This test is already being used in several resource-constrained contexts. The test is accurate, may yield findings in 15 to 20 minutes, and is easy to use. Rapid syphilis testing has been shown to aid in the detection of pregnant women with the disease, as these women do not have much time to cure it before giving birth and have a high chance of passing it on to their children. However, in most low- and middle-income countries, additional effort is needed to ensure that all pregnant women are tested for syphilis. Several rapid diagnostics for various STIs are being developed, with the potential to enhance STI diagnosis and treatment, especially in resource-limited conditions.
The rise in syphilis incidence and prevalence rates is a major element driving market expansion for syphilis testing. In the MSM (Men who have sex with men) population, injecting drug users, and sex workers, there are a growing number of new illnesses being spread. Furthermore, many cases of syphilis are asymptomatic during the infectious phase and hence go undetected.
Despite the availability of efficient therapies and formerly effective prevention techniques, syphilis has seen a major resurgence in the United States in the recent decade. The majority of cases occur among males who have sex with men (MSM); nevertheless, there has been a recent surge among premenopausal women, which coincides with an alarming increase in congenital cases. Syphilis' reappearance can be linked in part to shifting social and behavioral variables, particularly among young MSM.
The increasing individual and healthcare burden, the biological link between syphilis and human immunodeficiency virus (HIV) transmission and infection is particularly concerning. Furthermore, some individual acts and public health efforts aimed at reducing the risk of contracting HIV may instead result in risk compensation, making syphilis transmission easier. Because untreated syphilis is linked to negative health outcomes, both effective prevention and treatment measures for this systemic illness have significant short- and long-term implications for health.
The US market dominated the North America Syphilis Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $389.4 million by 2028. The Canada market is anticipated to grow at a CAGR of 7.5% during (2022 - 2028). Additionally, The Mexico market would experience a CAGR of 6.6% during (2022 - 2028).
Based on Type, the market is segmented into Primary & Secondary Syphilis and Others. Based on Location of Testing, the market is segmented into Laboratory testing and Point of care (POC) testing. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Syphilis Testing Market is Estimated to reach $1.5 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Siemens Healthineers AG, Abbott Laboratories, DiaSorin S.p.A. (Luminex Corporation), Hologic, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Cepheid), and F. Hoffmann-La Roche Ltd.
By Type
By Location of Testing
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 